Cambridge, MA – According to filings with the U.S. Securities and Exchange Commission, Black Diamond Therapeutics is raising $87,224,867.00 in a new round of investment. Sources indicate as part of senior management President and Chief Executive Officer, David Epstein played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Black Diamond Therapeutics

Black Diamond Therapeutics Inc. is a leading venture-backed biotechnology company focused on the discovery and development of precision medicine for cancer that are directed against a novel class of allosteric mutant oncogenes.

To learn more about Black Diamond Therapeutics, visit http://www.blackdiamondtherapeutics.com/

Contact:
David Epstein, President and Chief Executive Officer
617-417-5868
https://www.linkedin.com/in/elizabeth-buck-6486b271/

SOURCE: http://www.intelligence360.io
Copyright (c) 2019 SI360 Inc. All rights reserved